欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
(R)-Elagolix_834153-87-6_产品详情
834153-87-6
  • names:

    (R)-Elagolix

  • CAS号:

    834153-87-6

    MDL Number:
  • MF(分子式): C32H30F5N3O5 MW(分子量): 631.59
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
(R)-Elagolix
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM003721-5mg 5mg 98.06% ¥ 1485.00 ¥ 1485.00 2-3天
- +
¥ 0.00
YZM003721-2mg 2mg 98.06% ¥ 910.00 ¥ 910.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 834153-87-6
Inchi
InchiKey
分子式 Formula C32H30F5N3O5
分子量 Molecular Weight 631.59
溶解度Solubility 生物体外In Vitro:DMSO溶解度≥ 100 mg/mL(158.33 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
(R)-Elagolix(CAS:834153-87-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).
IntroductionElagolix is a highly potent, selective, orallyctive, shorturation, noneptide antagonist of the gonadotropineleasing hormone receptor (GnRHR) (KD = 54 pM).
Application1
Application2
Application3
Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM). Target: GnRH in vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Carr B, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341-1351.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents